theMednetRegister

Primary Care

Journal Club ft. NEJM publications   

Questions discussed in this category

How will your approach to screening and diagnosis of early dementia change given newly available therapies for early Alzheimer's disease?
5 Answers available
At what point do you consider a patient to have relapsing PMR?
How much cumulative prednisone exposure do you tolerate and how many attempts at tapering will you pursue before considering addition of a steroid spa...
4 Answers available
How will you approach tapering sarilumab in patients with PMR in remission?
After what interval of sustained remission will you attempt to taper, and will you do so by first widening the dosing interval?
2 Answers available
How will you adjust your approach to steroid taper in patients with PMR also on sarilumab?
2 Answers available
What baseline and ongoing testing do you recommend for patients with PMR who are going to be on a prolonged steroid taper?
Do you universally perform baseline DEXA and Hgb A1C? How often are you obtaining routine labs?
2 Answers available
What patient factors prompt you to consider starting dupilumab in patients with COPD?
Does active smoking status influence this decision?
2 Answers available
How do you counsel patients on the side effects of sodium phenylbutyrate and taurursodiol?
3 Answers available
How do you approach CV risk assessment in RA patients when RA itself is associated with some degree of increased CV risk at baseline?
Recent articles regarding the use of JAK-Inhibition in RA have suggested to avoid in patients with increased CV risk.  However, RA itself is cons...
2 Answers available
Would you recommend that a patient with stable coronary artery disease and well-controlled RA on a JAK inhibitor continue on their current therapy?
2 Answers available
Do you still plan to offer tofacitinib to RA patients over 65 if they have one or more additional CV risk factors?
2 Answers available
How do you counsel patients regarding the cardiovascular and cancer risks associated with tofacitinib?
2 Answers available


Papers discussed in this category

Ann Rheum Dis, 2016 Oct 03
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.
N Engl J Med,
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
N Engl J Med, 2020 Sep 3
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022 Aug 15
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
The journal of prevention of Alzheimer's disease, 2022
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force.
The New England journal of medicine, 2023 Oct 05
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
Open access rheumatology : research and reviews, 2016
Polymyalgia rheumatica: observations of disease evolution without corticosteroid treatment.
Ann Rheum Dis, 2015 Oct
2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.
JAMA, 2022 Sep 20
Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
Arthritis care & research, 2023 Oct 26
2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Rheumatology advances in practice, 2021 Nov 27
Fragility fractures and prescriptions of medications for osteoporosis in patients with polymyalgia rheumatica: results from the PMR Cohort Study.

Related Topics in Primary Care

Copyright © 2025 theMednet
All Rights Reserved.